Planar Systems cut list prices last month for its medical-grade flat-panel monitors by almost half, framing the move as part of an effort to make flat-panel display systems more affordable. The company's most popular product, a 3-megapixel dual-display
Planar Systems cut list prices last month for its medical-grade flat-panel monitors by almost half, framing the move as part of an effort to make flat-panel display systems more affordable. The company's most popular product, a 3-megapixel dual-display monitor, which was listed for $28,000 now lists for $15,000. Planar has maintained margins on its products by taking costs out of their manufacture. This was achieved by redesigning boards and outsourcing manufacturing to Asia, according to the company.
Planar executives said the price cuts should allow a wider range of healthcare facilities to deploy Planar displays. They noted, however, that the new prices on Planar's 2-, 3-, and 5- megapixel monitors bring the company more in line with competitors whose products deliver similar image quality.
Planar's decision to reduce list prices marked an evolutionary step in the sales history of flat-panel monitors: the transition from an early-adopter market to one of mass sales, according to Quest International, which distributes flat-panel medical monitors made by Totoku of Japan. Sales will increasingly be decided by software and support services, Planar and Quest executives agreed.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.